Gołkowski Filip, Jabrocka-Hybel Agata, Huszno Bohdan
Katedra i Klinika Endokrynologii, Collegium Medicum, Uniwersytetu Jagielloriskiego w Krakowie.
Przegl Lek. 2005;62(5):284-6.
Radioactive iodine (131I) is a well-established therapeutic modality in the treatment of toxic solitary autonomous thyroid nodules. This method is preferred in patients with small, benign nodules. The aim of our study was to investigate the effects of radioiodine therapy on thyroid size in patients with a solitary toxic thyroid nodule. 22 patients with single nodule in USG and confirmed "hot" nodule in scintigraphy were enrolled in the study. Thyroid and nodule volume were determined by ultrasound before, 3 and 6 months after the administration of 131I. Thyroid function was assessed by TSH level prior to the treatment and 6 weeks after the therapy. Thyroid volume and nodule size decreased significantly within 3 and 6 months after 131I treatment. The mean reduction of thyroid volume within 6 month after treatment was 32%. Reduction in thyroid volume and nodule, size was significantly greater within first 3 months than within next 3 months. Patients with smaller nodules (less than 70% of thyroid volume) were characterized by greater reduction of goiter size than patients with nodules bigger or equal to 70% of thyroid volume.
放射性碘(131I)是治疗毒性孤立性自主性甲状腺结节的一种成熟的治疗方式。对于小结节且为良性结节的患者,该方法是首选。我们研究的目的是调查放射性碘治疗对孤立性毒性甲状腺结节患者甲状腺大小的影响。22例超声检查显示为单个结节且闪烁扫描证实为“热”结节的患者纳入本研究。在给予131I之前、之后3个月和6个月通过超声测定甲状腺和结节体积。在治疗前及治疗后6周通过促甲状腺激素(TSH)水平评估甲状腺功能。131I治疗后3个月和6个月内甲状腺体积和结节大小显著减小。治疗后6个月内甲状腺体积的平均缩小率为32%。甲状腺体积和结节大小在前3个月的缩小幅度明显大于后3个月。结节较小(小于甲状腺体积的70%)的患者与结节大于或等于甲状腺体积70%的患者相比,甲状腺肿大缩小幅度更大。